EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
Clinical Pharmacy Services
Elena Elvira Ladrón de Guevara, Belen Sanchez Rodriguez, Misael Rodriguez Goicoechea, Marina Sanchez Valera, Diego Gámez Torres, Francisca Verdejo Reche, Inmaculada Alférez García
The main aim of this study is to find out the prescriptions of benzodiazepine derivatives from 2018 to 2021 in the context of the SARS COV 2 pandemic and the variation in them. As a secondary objective, we will learn which benzodiazepine derivatives varied more.
The most frequently recorded mental health problem is anxiety disorder and in the context of the SARS COV 2 pandemic, where an increase in anxiety cases has been evidenced, benzodiazepine derivatives (N05BA) have been one of the most prescribed pharmacological groups in most developed countries for this problem. Although its short-term benefits have been demonstrated, increasing its consumption may have long-term risks.
Retrospective, observational and cross-sectional study. The study period includes June 2018, June 2019, June 2020 and June 2021. The study population includes the 710.581 inhabitants associated with the prescribing doctors of benzodiazepine derivatives, from the study province.
N = 710,581, 21.61% (153,574) with a benzodiazepine prescription, 67.33% (103,416) women, between June 2018-June 2021. The prescribed benzodiazepine derivatives: alprazolam, Diazepam, diazepam / priridoxine, clotiazepam, lorazepam, ketazolam, clobazam, pinazepam, clorazepatodipotassium, bromazepam, bentazepam, diazepam / sulpiride, diazepam / sulpiride / pyridoxine.
June 2018: 35,800 prescriptions, 67’30% (24,085) women, June 2019: 37,601, 67.20% (25,262) women, June 2020: 39,547, 67.30% (26,622) women and June 2021: 40,626, 67, 60% (27,477) women.
From June 2018 to June 2019 prescriptions increased 5.03% (1,801), from June 2019 to June 2020 they increased 5.20% (1,946), from June 2020 to June 2021 they increased 2.73% ( 1,079), which represented a 13.48% increase in prescriptions from June 2018 to June 2021 (4,826).
The largest prescription increases were diazepam + 23%, lorazepam + 18%, bromazepam + 12.5%, and alprazolam + 12.3%. The largest prescription decreases were clotiazepam and bentazepam -100%, pinazepam -96’43% and clobazazam -22’45%.
Currently, the consumption of benzodiazepine derivatives has been increasing due to an increase in stress and anxiety situations and, in the context of the SARS VOC 2 pandemic, we have seen a progressive increase of 13.48% (4,826 prescriptions) from June 2018 to June 2021, with women being the user of 67.33% of prescriptions on average. These data allow us to know the current situation of the prescription of benzodiazepine derivatives to the population and to focus on mental health both in the validation of treatments and in pharmaceutical care.
